• Lipocine published an ASCP presentation on its Phase 3 placebo-controlled trial of LPCN 1154, an oral brexanolone candidate for postpartum depression.
• The trial missed its primary endpoint: HAM-D change at hour 60 was -12.0 vs -10.7 for placebo; LSM difference -1.3; p-value not significant.
• Safety profile appeared comparable to placebo: any TEAE 17.8% in each arm; no treatment-related severe or serious TEAEs reported.
• A post-hoc analysis excluding one outlier site showed nominally significant, placebo-adjusted HAM-D improvements at hour 12 (-7.1) and hour 60 (-5.8).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipocine Inc. published the original content used to generate this news brief on May 27, 2026, and is solely responsible for the information contained therein.